Moritz Stolla
Rochester, NYNPI 1700144532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Sanofi accounts for 83.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $403 and has fallen 94.6% since, to $22 in 2025.
Across 9 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$382
- Cerus Corporation$73
Across 37 payments — averaging $95,832 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cerus Corporation$2.3M
- Terumo BCT, Inc.$1.3M
What the payments were for
- Food & beverage$455100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 5 | $382 |
| Cerus Corporation | 4 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CABLIVI$111
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.